Which BNP Better Predicts CV Events in Stable Coronary Heart Disease?

MedicalResearch.com Interview with:
Rakesh K. Mishra, MD
San Francisco Veterans Affairs Medical Center
San Francisco, CA 94121.

Medical Research: What are the main findings of the study?

Dr. Mishra: Increased levels of both BNP and NT-proBNP are associated with elevated risk of adverse cardiovascular events in patients with stable coronary artery disease. However, when added to existing clinical models of risk, NT-proBNP is superior to BNP for risk reclassification.

Medical Research: Were any of the findings unexpected?

Dr. Mishra: Prior literature has suggested that BNP and NT-proBNP are equivalent markers of risk in stable coronary artery disease. We, however, found that, though both B-type natriuretic peptides are associated with risk of adverse cardiovascular events, NT-proBNP performs better than BNP for risk classification.

Medical Research: What should clinicians and patients take away from your report?

Dr. Mishra: When determining risk of adverse cardiovascular events in stable coronary artery disease, both BNP and NT-proBNP enhance risk models consisting of clinical variables alone. However, NT-proBNP may be superior to BNP for risk classification.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Mishra :Future research should determine whether the differences we noted between NT-proBNP and BNP in stable coronary disease also hold in other disease states such as acute coronary syndrome, asymptomatic severe aortic stenosis, chronic kidney disease, etc.


B‐type Natriuretic Peptides for the Prediction of Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study

Rakesh K. Mishra, Alexis L. Beatty, Rajesh Jaganath, Mathilda Regan, Alan H.B. Wu, and Mary A. Whooley

J Am Heart Assoc. 2014;3:e000907, originally published July 22, 2014, doi:10.1161/JAHA.114.000907